There is an unusually high frequency of CTL clones that recognize allogeneic MHC molecules. While recognition of MHC determinants, per se, has been thought to underlay this phenomenon, recent structural, biochemical, and cellular studies have indicated that the peptide binding groove of the MHC molecule may normally be occupied by endogenously synthesized peptide. This suggests endogenous peptides may contribute to allorecognition. The applicant has recently obtained direct evidence that such peptide-dependent allorecognition is possible for CTL clones specific for H-2Kb. Further, peptides recognized in association with class I appear to be differentially expressed by cells of different origin. This proposal will analyze the generality of these findings and determine their applicability to define self and tumor antigens. CTL raised against Kb expressed on normal or tumor cell lines will be assessed for recognition of Kb expressed on normal cells, tumor cells, or cells of different species that have been transfected with the Kb gene. CTL clones which discriminate among such targets will be further analyzed to define the role of endogenous peptide in Kb recognition. Peptides prepared by cleavage of cytoplasmic proteins from cells recognized by such CTL will be used to sensitize Kb expressing cells which are not recognized. Where recognition appears to be specific for a tumor associated antigen, the capacity of such allogeneic CTL clones to eliminate tumor cells in vivo will be assessed. To learn more about the origin of the peptide antigens defined by allo-CTL, the hypothesis that they are derived from a select group of cellular proteins will be tested by biochemically purifying cytoplasmic proteins prior to cleavage into peptides. In all cases, proof that CTL clones recognize either class I plus a specific peptide or class I, per se, will be obtained using a cell free system for CTL triggering in which stimulatory antigen is provided in the form of purified immobilized class I molecules and specific peptide antigens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA052856-03
Application #
3197703
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1990-09-01
Project End
1995-02-28
Budget Start
1992-03-01
Budget End
1993-02-28
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Lustgarten, J; Theobald, M; Labadie, C et al. (1997) Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol 52:109-18
Morgan, D J; Liblau, R; Scott, B et al. (1996) CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 157:978-83
Theobald, M; Biggs, J; Dittmer, D et al. (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993-7
Chattopadhyay, S; Theobald, M; Biggs, J et al. (1994) Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity. J Exp Med 179:213-9
Sherman, L A; Chattopadhyay, S; Biggs, J A et al. (1993) Alloantibodies can discriminate class I major histocompatibility complex molecules associated with various endogenous peptides. Proc Natl Acad Sci U S A 90:6949-51
Kane, K P; Sherman, L A; Mescher, M F (1991) Exogenous beta 2-microglobulin is required for antigenic peptide binding to isolated class I major histocompatibility complex molecules. Eur J Immunol 21:2289-92